A series of in vitro experiments were performed to determine the shortest length of oligosaccharide capable of competing CXCL12 from a solid-phase of heparin or heparan sulphate matrix and inhibiting breast cancer cell migration, while exerting little or no anticoagulant effect. This evidence concerns the gene CXCL12 and breast cancer.